The beta coefficient, which shows the direction and magnitude of the effect of semaglutide on alcohol use, is negative in all three outcomes, suggesting an overall reduction of alcohol consumption in all measurements, including the BrAC or estimated grams per alcohol consumed
Individualised drug therapy for cardiovascular risk reduction Many cardiovascular outcome trials have examined the effect of novel glucose-lowering drugs on cardiovascular safety
As a result, HbA 1c targets may not need to be adjusted for older adults, as is currently advised by the ADA [6], when using glucose-lowering treatment with a low intrinsic risk of hypoglycemia
Rapamycin has also been studied for its ability to support immune function, improve metabolic health, and extend lifespan by mimicking the effects of caloric restriction
[DOI] [PMC free article] [PubMed] [Google Scholar] 110.Dalle S, Ravier MA, Bertrand G